Cairo, August 15, 2023 – “Korra Energi,” the leading company in contracting, energy efficiency, Industrial trading, and utilities, signed this morning a contract with MEVAC, the Middle East Veterinary Vaccines Company, for the implementation of civil, construction, and finishing works for three factories for MEVAC and U-vac. MEVAC is the first Egyptian company manufacturing veterinary vaccines and is a national project that has obtained the gold license. This project is a strong addition to the national projects currently being implemented by Korra Energi, including the national project for the development of the Fustat area and the construction of the Maghagha General Hospital as part of the “Decent Life” projects.

Engineer Ayman Korra, Chairman of the Board of Korra Energi, expressed his happiness with the project, saying, “We are pleased to collaborate with a large company like MEVAC. We consider all the companies we work with as our partners in success and achieving “E3mar El Ard” growth and prosperity. We are proud to be the first choice for our customers, especially in the healthcare, pharmaceutical, and hospitality sectors. We are also proud of our contribution to national projects and the development of the Egyptian state. We have a history of 25 years of achievements with a total of 225 projects executed by our distinguished team of over 2,000 members with exceptional engineering and technical capabilities. We excel in projects that require advanced engineering capabilities, such as national projects, electromechanical works, retrofitting, and renovation.”

Dr. Magdy El-Sayed, Chairman of the Board of MEVAC, stated, “We chose Korra Energi to implement the project based on their excellence in executing such major projects. We have a major expansion plan for the production of veterinary vaccines to meet the needs of the local market and export to foreign markets, in line with the Egyptian state’s plan to localize pharmaceutical industries and make Egypt a center for providing pharmaceutical products to Africa. We are working to achieve this through the expansion of building new vaccine factories.”

The MEVAC factories project includes three buildings. The first building consists of four floors with a total area of 6,520 square meters, dedicated to expanding the production of avian influenza vaccines, with a production capacity of 3.6 billion doses to meet the needs of Egypt and importing countries, which currently include 26 countries and is planned to expand to more than 46 countries in the next three years and reach over 90 countries in the next ten years.

The second building is a four-story building with a total area of 8,367 square meters, which will be the first specialized factory for producing genetically engineered vaccines for the animal and poultry wealth sectors. It will have a production capacity covering Egypt, the Middle East, Africa, and Asian markets, estimated at 4 billion loaded vaccine doses and over 5 billion live vaccine doses.

The third building, Building 5, with a total area of 9,000 square meters, will be allocated for the research and development center to serve the entire region with human and veterinary vaccines, in addition to the presence of an administrative department to serve the entire factory area.